Skip to content

Released Nov 7, 2016, after the close

10-Q filed Nov 7, 2016, 38 days after period end · 0001193125-16-761702

Q3 2016 · 10-Q
Revenue$48.00K−36.0% vs Q3 2015−18.6% vs Q2 2016
Net Income-$25.43MN/M vs Q3 2015N/M vs Q2 2016
EPS Diluted-$0.69N/M vs Q3 2015N/M vs Q2 2016
Operating Income-$25,742,000N/M
Operating Cash Flowderived-$20,334,000N/M
Free Cash Flowderived-$20,334,000N/M
Margins · derived
Operating margin-53629.2%−12815.8 pt vs Q3 2015
Net margin-52968.8%−12471.4 pt vs Q3 2015

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ3 2016Q3 2015Q3 2014Q3 2013
Revenue$48.00K$75.00K$21.00K$0.00
Net Income-$25.43M-$30.37M-$19.72M—
EPS Diluted-$0.69-$0.85-$0.61-$3.66

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Karyopharm Therapeutics Inc. · CIK 1503802 · Engraved from SEC EDGAR